...
首页> 外文期刊>Cancer immunology, immunotherapy : >Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
【24h】

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential

机译:具有治疗潜力的HLA限制和人巨细胞病毒特异性抗体曲目的表征

获取原文
获取原文并翻译 | 示例
           

摘要

With an infection rate of 60-90%, the human cytomegalovirus (HCMV) is very common among adults but normally causes no symptoms. When T cell-mediated immunity is compromised, HCMV reactivation can lead to increased morbidity and mortality. HCMV antigens are processed and presented as peptides on the cell surface via HLA I complexes to the T cell receptor (TCR) of T cells. The generation of antibodies against HCMV peptides presented on HLA complexes (TCR-like antibodies) has been described, but is without therapeutic applications to date due to the polygenic and polymorphic nature of HLA genes. We set out to obtain antibodies specific for HLA/HCMV-peptides, covering the majority of HLA alleles present in European populations. Using phage display technology, we selected 10 Fabs, able to bind to HCMV-peptides presented in the 6 different HLA class I alleles A*0101, A*0201, A*2402, B*0702, B*0801 and B*3501. We demonstrate specific binding of all selected Fabs to HLA-typed lymphoblastoid cell lines (EBV-transformed B cells) and lymphocytes loaded with HCMV-peptides. After infection with HCMV, 4/10 tetramerized Fabs restricted to the alleles HLA-A*0101, HLA-A*0201 and HLA-B*0702 showed binding to infected primary fibroblasts. When linked to the pseudomonas exotoxin A, these Fab antibodies induce highly specific cytotoxicity in HLA matched cell lines loaded with HCMV peptides. TCR-like antibody repertoires therefore represent a promising new treatment modality for viral infections and may also have applications in the treatment of cancers.
机译:人类巨细胞病毒(HCMV)感染率为60-90%,在成年人中非常常见,但通常不会引起症状。当T细胞介导的免疫功能受损时,HCMV再激活可导致发病率和死亡率增加。HCMV抗原通过HLA I复合物在T细胞的T细胞受体(TCR)表面被处理并呈现为肽。已经描述了针对HLA复合物上呈现的HCMV肽的抗体(TCR样抗体)的产生,但由于HLA基因的多基因和多态性,迄今为止没有治疗应用。我们着手获得针对HLA/HCMV肽的特异性抗体,覆盖欧洲人群中存在的大多数HLA等位基因。利用噬菌体展示技术,我们选择了10个能够与6个不同HLA I类等位基因A*0101、A*0201、A*2402、B*0702、B*0801和B*3501中呈现的HCMV肽结合的Fab。我们证明了所有选择的Fab与HLA型淋巴母细胞系(EBV转化的B细胞)和携带HCMV肽的淋巴细胞的特异性结合。感染HCMV后,4/10限制于HLA-A*0101、HLA-A*0201和HLA-B*0702等位基因的四聚体Fab与感染的原代成纤维细胞结合。当与假单胞菌外毒素A相连时,这些Fab抗体在负载HCMV肽的HLA匹配细胞系中诱导高度特异性细胞毒性。因此,TCR样抗体库代表了一种有希望的病毒感染新治疗模式,并可能在癌症治疗中有应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号